These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 1814896)

  • 41. Blood disorders: future trends in iron chelation.
    Jordan D; Kontoghiorghes G
    Nurs Stand; 1990 Oct 24-30; 5(5):25-7. PubMed ID: 2124864
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pilot study on parental stress and behavioral adjustment to the thalassemia major disease process in children undergoing iron-chelation in western Taiwan.
    Kuo HT; Peng CT; Tsai MY
    Hemoglobin; 2006; 30(2):301-9. PubMed ID: 16798655
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols.
    Kolnagou A; Economides C; Eracleous E; Kontoghiorghes GJ
    Hemoglobin; 2008; 32(1-2):41-7. PubMed ID: 18274982
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Iron chelation.
    Hershko C; Link G; Pinson A
    Prog Clin Biol Res; 1989; 309():133-40. PubMed ID: 2675082
    [No Abstract]   [Full Text] [Related]  

  • 45. Effects of chelation therapy on cardiac function improvement in thalassemia patients: literature review and the Taiwanese experience.
    Peng CT; Tsai CH; Wu KH
    Hemoglobin; 2008; 32(1-2):49-62. PubMed ID: 18274983
    [TBL] [Abstract][Full Text] [Related]  

  • 46. T2* magnetic resonance and myocardial iron in thalassemia.
    Pennell DJ
    Ann N Y Acad Sci; 2005; 1054():373-8. PubMed ID: 16339685
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ
    Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Oral iron chelation is here.
    Kontoghiorghes GJ
    BMJ; 1991 Nov; 303(6813):1279-80. PubMed ID: 1747667
    [No Abstract]   [Full Text] [Related]  

  • 49. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
    Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combined chelation therapy with deferoxamine and deferiprone in β-thalassemia major: compliance and opinions of young thalassemic patients.
    Hatzipantelis ES; Karasmanis K; Perifanis V; Vlachaki E; Tziomalos K; Economou M
    Hemoglobin; 2014; 38(2):111-4. PubMed ID: 24351163
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Thalassemia: Yesterday, Today, Tomorrow.
    Hadjidemetriou M
    Am J Hematol; 2017 Jun; 92(6):490-492. PubMed ID: 28370242
    [No Abstract]   [Full Text] [Related]  

  • 52. Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years.
    Poggi M; Sorrentino F; Pugliese P; Smacchia MP; Daniele C; Equitani F; Terlizzi F; Guitarrini MR; Monti S; Maffei L; Losardo A; Pasin M; Toscano V
    Ann Hematol; 2016 Apr; 95(5):757-63. PubMed ID: 26957357
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Iron chelation therapy in hereditary hemochromatosis and thalassemia intermedia: regulatory and non regulatory mechanisms of increased iron absorption [Kontoghiorghes GJ, Spyrou A, Kolganou A. Hemoglobin. 2010;34(3); 251-264].
    Nick HP
    Hemoglobin; 2011; 35(2):175-9. PubMed ID: 21417578
    [No Abstract]   [Full Text] [Related]  

  • 54. Iron chelation therapy for transfusional iron overload: a swift evolution.
    Musallam KM; Taher AT
    Hemoglobin; 2011; 35(5-6):565-73. PubMed ID: 21910602
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Deferiprone.
    Piga A; Roggero S; Salussolia I; Massano D; Serra M; Longo F
    Ann N Y Acad Sci; 2010 Aug; 1202():75-8. PubMed ID: 20712776
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Olivieri case.
    Constantinou G; Melides S; Modell B
    N Engl J Med; 2003 Feb; 348(9):860-3; author reply 860-3. PubMed ID: 12606746
    [No Abstract]   [Full Text] [Related]  

  • 57. Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*.
    Kolnagou A; Economides C; Eracleous E; Kontoghiorghes GJ
    Hemoglobin; 2006; 30(2):219-27. PubMed ID: 16798647
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Overview of iron chelation therapy with desferrioxamine and deferiprone.
    Cappellini MD; Musallam KM; Taher AT
    Hemoglobin; 2009; 33 Suppl 1():S58-69. PubMed ID: 20001633
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine.
    Giardina PJ; Grady RW
    Semin Hematol; 1995 Oct; 32(4):304-12. PubMed ID: 8560288
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Retinal abnormalities in β-thalassemia major.
    Bhoiwala DL; Dunaief JL
    Surv Ophthalmol; 2016; 61(1):33-50. PubMed ID: 26325202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.